For example, CD19-targeted CAR-T cells with co-expressing of the chimeric switch receptor of PD-1/CD28 were examined for the treatment of patients with R/R DLBCL in phase I clinical trial (199). This evidence concerns the gene CD28 and diffuse large B-cell lymphoma.